Elekta develops precision radiation medicine used to treat a range of cancers, including brain tumours, breast cancer, kidney cancer, lung cancer, pancreatic cancer and prostate cancer, as well as certain neurological disorders.
Elekta has raised €100M across 1 funding round from 1 investor, most recently a Debt round in Aug 2026. Based in Stockholm, Sweden; active in Healthtech. Data as of 1 Sept 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-08-31 | Debt | €100M |
| European Investment Bank (EIB) |
| View deal → |
